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Abstract
Background: Mercury is known to be neurotoxic, but its effects on the immune system are less well known. Mast
cells are involved in allergic reactions, but also in innate and acquired immunity, as well as in inflammation. Many
patients with Autism Spectrum Disorders (ASD) have “allergic” symptoms; moreover, the prevalence of ASD in
patients with mastocytosis, characterized by numerous hyperactive mast cells in most tissues, is 10-fold higher than
the general population suggesting mast cell involvement. We, therefore, investigated the effect of mercuric
chloride (HgCl2) on human mast cell activation.
Methods: Human leukemic cultured LAD2 mast cells and normal human umbilical cord blood-derived cultured
mast cells (hCBMCs) were stimulated by HgCl2 (0.1-10 μM) for either 10 min for beta-hexosaminidase release or
24 hr for measuring vascular endothelial growth factor (VEGF) and IL-6 release by ELISA.
Results: HgCl2 induced a 2-fold increase in b-hexosaminidase release, and also significant VEGF release at 0.1 and
1 μM (311 ± 32 pg/10
6 cells and 443 ± 143 pg/10
6 cells, respectively) from LAD2 mast cells compared to control
cells (227 ± 17 pg/10
6 cells, n = 5, p < 0.05). Addition of HgCl2 (0.1 μM) to the proinflammatory neuropeptide
substance P (SP, 0.1 μM) had synergestic action in inducing VEGF from LAD2 mast cells. HgCl2 also stimulated
significant VEGF release (360 ± 100 pg/10
6 cells at 1 μM, n = 5, p < 0.05) from hCBMCs compared to control cells
(182 ± 57 pg/10
6 cells), and IL-6 release (466 ± 57 pg/10
6 cells at 0.1 μM) compared to untreated cells (13 ± 25
pg/10
6 cells, n = 5, p < 0.05). Addition of HgCl2 (0.1 μM) to SP (5 μM) further increased IL-6 release.
Conclusions: HgCl2 stimulates VEGF and IL-6 release from human mast cells. This phenomenon could disrupt the
blood-brain-barrier and permit brain inflammation. As a result, the findings of the present study provide a
biological mechanism for how low levels of mercury may contribute to ASD pathogenesis.
Background
Heavy metals such as mercury result in neurological
injury that may lead to developmental defects, periph-
eral neuropathies, and enhanced neurodegenerative
changes [1]. Mercurials may be found in various drugs,
in bleaching creams, antiseptics, disinfectants, as preser-
vatives in cosmetics, tooth pastes, lens solutions, vac-
cines, contraceptives and immunotherapy solutions,
fungicides, herbicides and in dental fillings, as well as in
fish such as tuna due to water pollution [2]. Mercury
can cause immune, sensory, neurological, motor, and
behavioral dysfunction similar to those associated with
Autism Spectrum Disorders (ASD) [2]. The possible role
of mercury used as preservative in vaccines [2] has been
debated extensively, but most epidemiological studies do
not support a causal association between vaccines and
autism [3-7]. However, 87% of children included in the
US Vaccine Adverse Event Reporting System (VAERS)
had ASD [8]. Moreover, a paper based on computerized
medical records in the Vaccine Safety Data-link con-
cluded there was “significantly increased rate ratios for
ASD with mercury exposure from thiomerosal-contain-
ing vaccines” [9]. Mercury has been shown to induce
proliferation and cytokine production from T lympho-
cytes [10]. Mercuric chloride (HgCl2)i nn o n t o x i cd o s e s
induces the release of histamine and cytokines, such as
IL-4 and tumor necrosis factor-alpha (TNF-a), from a
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derived cultured mast cells [11]. HgCl2 (100 μM) also
enhances immunoglobulin E-mediated mediator release
from human basophils [12], and histamine release from
a rat basophil cell line (RBL-2H3) [13].
We, therefore, investigated whether HgCl2 could stimu-
late human mast cells, an action that could be enhanced
in subjects who already have an atopic background.
Methods
HgCl2 was obtained from Fluka Chemical Corp. (Mil-
waukee, WI) and was diluted in Dulbecco’sp h o s p h a t e
buffered saline (DPBS, GIBCO, Grand Island, NY) on
the day of the experiments.
Human mast cell culture
LAD2 and human umbilical cord blood-derived cultured
mast cells (hCBMCs) were cultured as previously
described [14,15]. Umbilical cord blood was collected as
approved by the Tufts Medical Center’s( B o s t o n ,M A )
Investigation Review Board in tubes containing 10 U/ml
heparin, blood was diluted 1:2 with DPBS, GIBCO) con-
taining 2 mM ethylenediaminetetraacetic acid (Sigma,
St. Louis, MO). Non-phagocytic mononuclear cells were
separated by density-gradient centrifugation using Lym-
phocyte Separation Medium (LSM) from Organon
Teknika Corp. (Durham, NC). The isolation of hemato-
poietic stem and progenitor cells (CD34
+) was performed
by positive selection of AC133-expressing cells by mag-
netic-associated cell sorting (MACS) using an AC133 cell
isolation kit (Milltenyi Biotec, Auburn, CA) as reported
previously [15,16]. CD34
+ cells were suspended in AIM-V
Medium (GIBCO BRL), supplemented with 100 to 200
ng/ml recombinant human stem cell factor (rhSCF,
Amgen, Thousand Oaks, CA), 50 ng/ml IL-6 (Millipore,
Temecula, CA) and cultured for 12 to 16 weeks. During
this culture period, the cells were washed with DPBS every
week and resuspended using fresh culture medium. The
purity of hCBMCs was evaluated by immunocytochemical
staining for tryptase as previously described [15]. Mast cell
viability was determined by Trypan blue (0.3%) exclusion
method. LAD2 cells cultured over 10 days and hCBMCs
cultured over 12 weeks were used for the experiments.
Histamine assay
LAD2 or hCBMCs cells were washed with DPBS and
mast cell media, once in each. Cell suspensions (5 × 10
4
cells per tube, 500 μl/sample) were preincubated with
either the neuropeptide substance P (SP, 0.1-2 μM) or
anti-IgE (10 μg/ml) as positive controls, or HgCl2 (1-10
μM) for 30 min. After the reaction, the cells were cen-
trifuged and the supernatant fluid was collected.
Histamine levels were assayed using EIA histamine kit
(# IM2015; Immunotech, Beckman Coulter Company,
France) as per the directions. Histamine release was cal-
culated as percent of total.
b-Hexosaminidase assay
b-Hexosaminidase release, as an index of mast cell
degranulation, was assayed using a fluorometric assay as
previously reported [17]. Briefly, b-hexosaminidase activ-
ity in the supernatant fluid and cell lysates (LAD2 cells,
0.5 × 10
5/tube, were lysed with 1% Triton X-100 to
measure residual cell-associated b-hexosaminidase) were
incubated with substrate solution (p-nitrophenyl-N-
acetyl-b-D-glucosaminide from Sigma, St Louis, MO) in
0.1 M citrate buffer (pH 4.5) for 60 min at 37°C. The
reaction was terminated by the addition 0.2 M NaOH/
0.2 M glycine. Absorbance was read at 405 nm in an
enzyme-linked immunosorbent assay reader, and the
results are expressed as the percentage of b-hexosamini-
dase activity released over the total.
Cytokine assay
LAD2 cells or hCBMCs were washed with DPBS, sterile
Tyrode’s buffer, and plain culture medium, once in
each, and were suspended in complete culture medium
without IL-6 (for hCBMCs). The LAD 2 cells or
hCBMCs (2 × 10
5 cells/well/200 μl) were plated in 96-
well, flat-bottom Falcon cell culture plates (Becton Dick-
inson) and were pre-incubated for 15 min at 37°C in a
5% CO2 incubator. The cells were then incubated with
either neuropeptide SP (0.1-2 μM) or HgCl2 (1-10 μM)
for 24 hours at 37°C. Control cells were treated with
equal volumes of only the respective culture medium.
After the reaction time, plates were centrifuged and the
supernatant medium was gently collected from the wells
and stored at -80°C until the cytokines were measured
by enzyme-linked immunosorbent assay (ELISA) using a
commercial kit (Quantikine, R&D Systems, Minneapolis,
MN), as reported previously [18]. The minimum detect-
able levels of VEGF and IL-6 were 5 pg/ml. Cell viability
was assessed at 1 hour and at 24 hours using the Try-
pan blue exclusion method.
Statistical analysis
All conditions were performed in triplicate, and all
experiments were repeated five times (n = 5). Results
are presented as mean ± SD. Data from two conditions,
such as stimulated and control samples, were compared
using the Unpaired 2-tailed Student’s t-test. Significance
of comparisons is denoted by p < 0.05.
Results
Effects of HgCl2 on mast cell viability
LAD2 mast cells and hCBMCs were incubated with
HgCl2 for 1 hour or for 24 hours in their respective
media, and cell viability was assessed by Trypan blue
Kempuraj et al. Journal of Neuroinflammation 2010, 7:20
http://www.jneuroinflammation.com/content/7/1/20
Page 2 of 7exclusion. HgCl2 reduced viability of LAD2 mast cells in
culture medium only slightly (10%), only at concentra-
tion of 10 μM, and only after 24 hours of incubation
( n=3 ,F i g .1 A ) .H g C l 2 reduced viability of hCBMCs by
25% at concentration of 10 μM after 24 hours of incuba-
tion (n = 5; Fig. 1B).
Effects of HgCl2 on LAD2 mast cell histamine release
We first tried to study the effect of HgCl2 on mast cell
histamine release. We assayed histamine release from
LAD2 mast cells and hCBMCs after incubation with
HgCl2 (1-10 μM) for another 30 min at 37°C in Tyrode’s
buffer. Addition of HgCl2 for 30 min induced statisti-
cally significant histamine release from hCBMCs, com-
pared to control cells, at HgCl2 concentrations of 0.1
and 1 μM. However, as the results were inconsistent
due to interference of HgCl2 with the histamine assay,
we do not present them. Instead, we investigated the
effect of HgCl2 on the release of b-hexosaminidase,
another secretory granule marker that is released in par-
allel with histamine. Only 10 μMH g C l 2 was able to
i n d u c ea2 - f o l di n c r e a s ei nb-hexosaminidase release
(Fig. 2A, n = 5, p < 0.05).
Effects of HgCl2 on LAD2 mast cell VEGF release
We then investigated whether HgCl2 could stimulate
release of proinflammatory mediators from mast cells.
LAD2 mast cells released significantly more VEGF at
HgCl2 concentrations of 0.1 and 1 μM (311 ± 32 pg/10
6
cells and 443 ± 143 pg/10
6 cells, respectively, compared
to 227 ± 17 pg/10
6 cells for control cells, p < 0.05, Fig.
2B). HgCl2 (0.1 μM) had a statistically significant syner-
gistic effect on LAD2 mast cell VEGF release (693 ± 102
pg/106 cells) when added with SP (0.1 μM) (Fig. 2B).
Combinations of higher concentrations of HgCl2 and SP
did not induce any additional VEGF release.
Effects of HgCl2 on hCBMC VEGF and IL-6 release
HgCl2 (1 μM) also induced release of significantly more
VEGF (182 ± 57 pg/10
6 cells) from hCBMCs (n = 5, p <
0.05) compared to control cells (360 ± 100 pg/10
6 cells)
(Fig. 3A).
Figure 1 Effects of HgCl2 on (A) LAD2 mast cells and (B) hCBMCs viability assayed by supravital staining with Trypan blue. LAD2 mast
cells and hCBMCs were incubated with HgCl2 one hour or 24 hours at 37°C and the viability was assayed (n = 3).
Kempuraj et al. Journal of Neuroinflammation 2010, 7:20
http://www.jneuroinflammation.com/content/7/1/20
Page 3 of 7LAD2 mast cells cannot synthesize IL-6. We, there-
fore, investigated the effect of HgCl2 on IL-6 release
from hCBMCs. HgCl2 (0.1 and 1 μM) significantly
induced IL-6 release (466 ± 57 pg/10
6 cells and 204 ±
47 pg/10
6 cells, respectively) compared to untreated
control cells (13 ± 25 pg/10
6 cells, n = 5, Fig. 3B). SP (5
μM), used as a positive control, also significantly
increased IL-6 release (609 ± 57 pg/10
6 cells) from
hCBMCs. Addition of HgCl2 (0.1) with SP (5 μM)
further increased IL-6 release to 745 ± 117 pg/10
6 cells
(Fig. 3B).
Discussion
This is the first report to our knowledge showing that
inorganic mercury in concentrations as low as 0.1 μM
can induce VEGF and IL-6 release from human cultured
mast cells. We also report for the first time that mer-
cury has a significant synergistic effect with SP (0.1 μM)
on VEGF release; this amount of VEGF release is higher
than what has previously been reported for hCBMCs
[19]. One paper has reported that HgCl2 can induce
release of histamine from primary lung and human leu-
kemic mast cells (HMC-1 cells), but only at toxic levels
of 0.33 mM [20]. Here we show that HgCl2 induces b-
hexosaminidase release, but only at a concentration of
10 μM. Mercury (10 μM) has previously been shown to
induce release of b-hexosaminidase, IL-4 and TNF-a
f r o mam u r i n em a s tc e l ll i n ea n df r o mm o u s eb o n e
marrow-derived cultured mast cells; the secretion of
Figure 2 Effects of HgCl2 on (A) b-hexosaminidase and (B)
VEGF release from LAD2 mast cells. LAD2 mast cells were
incubated with HgCl2 and/or SP as indicated for 10 min for b-
hexosaminidase and 24 hours for VEGF release at 37°C. The cells
were then centrifuged and the supernatant fluid was collected.
VEGF release was assayed by ELISA, while b-hexosaminidase release
was assayed spectrophotometrically (n = 5, *p < 0.05).
Figure 3 Effects of HgCl2 on VEGF release from hCBMCs.M a s t
cells were incubated with HgCl2 and/or SP as indicated for 24 hours
at 37°C. The cells were then centrifuged and the supernatant fluid
was collected. VEGF (A) and IL-6 (B) release from hCBMCs was
assayed by ELISA (n = 5, *p < 0.05).
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follows FcepsilonRI-induced mast cell activation [11]. In
contrast, HgCl2 does not have an effect on its own on
release of histamine and IL-4 from human basophil, but
only enhances allergic release at concentrations of 1 and
10 μM [12]. This is also true for IL-4 release from rat
mast cells [21]. Clinical symptoms of mercury poisoning
may be expected at blood levels of 1 μM [12]. However,
brain mast cells may react to lower mercury concentra-
tions, especially in vulnerable patient subpopulations.
Mast cells, by virtue of their location in the skin,
respiratory tract, and gastrointestinal system are poten-
tial targets for environmental agents with immunotoxic
effects [22]. Mast cells are critical not only for allergic
reactions, but also important in both innate and
acquired immunity [23], as well as in inflammation [24].
In view of the fact that a subgroup of ASD patients
have allergy symptoms that do not appear to be trig-
gered by IgE, it is noteworthy that mast cells can be sti-
mulated by non-allergic triggers originating in the gut
or the brain [24], especially neuropeptides such as SP
[25] and neurotensin (NT) [26]. Once activated, mast
cells secrete numerous vasoactive, neurosensitizing and
proinflammatory molecules that are relevant to ASD;
these include histamine, proteases, VEGF, prostaglandin
D2, as well as cytokines such as IL-6 [24]. In particular,
mast cells can secrete VEGF [27,28], an isoform of
which is vasodilatory [29] and is over expressed in
delayed hypersensitivity reactions [30]. In fact, mast cells
can release VEGF [31], IL-6 [32] and other mediators
“selectively” without degranulation [33]. Such mediators
could disrupt the gut-blood and blood-brain barriers
(BBB) permitting brain inflammation [34]. It is impor-
tant to note that mercury can cross the BBB through a
transport mechanism that can lead to significant brain
concentrations, and that can persist for prolonged peri-
ods of time [2,35]. Activated brain mast cells can disrupt
the BBB [36,37] and further increase brain mercury
levels.
The mechanisms of heavy metal neurotoxicity are not
fully understood. Mercury increases cytosolic calcium
levels in PC12 cells [38], and thimerosal does so in thy-
mus lymphocytes [39]. Mercury may also increase cellu-
l a ro x i d a t i v es t r e s ss i n c en e u r o n sa r eh i g h l ys u s c e p t i b l e
to reactive oxygen species (ROS) and neuronal mito-
chondria are especially vulnerable to oxidative damage
[40]. In fact, the primary dietary source of neurotoxic
mercury compounds is via the ingestion of methylmer-
cury from fish, which has been previously linked to
neurological damage [41].
Mercury’s activation of mast cell inflammatory media-
tor release may enhance allergic reactions in atopic indi-
viduals and exacerbate IgE-dependent diseases [12].
Allergic symptomatology is often present in ASD patients
[34], and a survey of children with ASD in Italy reported
that the strongest association was with a history of aller-
gies [42]. Moreover, a recent study reported increased
atopic diseases, as well as elevated serum IgE and eosino-
phils in Asperger patients [43]. In a National Survey of
Children’s Health, parents of autistic children reported
symptoms of allergies more often than other children,
with food allergies showing the greatest difference [44]. A
case series study also reported higher rate of food aller-
gies in ASD children [45]. In one study, 30% of autistic
children (n = 30) had a history of atopy as compared to
2.5% of age-matched “neurologic controls” (n = 30), but
there was no difference in serum IgE or in skin prick
tests to 12 common antigens [46], implicating triggers
other than IgE. In another study, ASD patients did not
have increased incidence of allergic asthma or allergic
dermatitis [42], but this study included only ASD patients
that were positive to RAST/skin testing. Finally, a preli-
minary report indicated that the prevalence of ASD may
be 10-fold higher [47] than the general population (1/100
children) in mastocytosis patients [48], characterized by
increased number of hyperactive mast cells in many
tissues, with symptoms that include allergies, food intol-
erances and “brain fog” [49,50].
Some epidemiological studies have failed to find a sig-
nificant relationship between mercury exposure from
vaccines and autism [3-7]. Nevertheless, 87% of children
included in the US Vaccine Adverse Event Reporting
System (VAERS) have ASD [8]. Moreover, a paper
based on computerized medical records in the Vaccine
Safety Datalink concluded there was “significantly
increased rate ratios for ASD with mercury exposure
from Thimerosal-containing vaccines” [9]. Also, there
are a series of epidemiological studies conducted in the
USA that have found significant associations between
environmental sources of mercury exposure and ASDs
[51]. In addition, patients with severe ASD have
evidence of significantly increased urinary porphyrins
consistent with mercury intoxication [52-55]. Mercury
toxicity may also affect critical methylation pathways in
vulnerable cells [56].
ASD are a group of pervasive developmental disorders
that include autistic disorder, Asperger’sd i s o r d e r ,a n d
atypical autism - also known as pervasive developmental
disorder-not otherwise specified (PDD-NOS). These are
neurodevelopmental disorders diagnosed in early child-
hood [57]. They are characterized by various degrees of
dysfunctional communication and social skills, repetitive
and stereotypic behaviors, as well as attention, cognitive,
learning and sensory defects [57,58]. ASD cases have
increased more than 10-fold during the last decade to a
prevalence of 1/100 children [44,57,59]. However, there
is no known distinct pathogenesis, there are no biomar-
kers, and there is no effective treatment [60].
Kempuraj et al. Journal of Neuroinflammation 2010, 7:20
http://www.jneuroinflammation.com/content/7/1/20
Page 5 of 7ASD may result from a combination of genetic/bio-
chemical susceptibility and epigenetic exposure to envir-
onmental factors, including reduced ability to excrete
mercury and/or exposure to mercury at critical develop-
mental periods [2,56]. A number of papers have sug-
gested that ASD may be associated with immune
dysfunction [61], while a recent review made the case
that ASD may be a neuroimmune disorder involving
mast cell activation [34].
Conclusions
The results of the present study support the biological
plausibility of how mercury could contribute to ASD
pathogenesis by inducing VEGF and IL-6 release from
mast cells, and as a result disrupt the BBB and thus per-
mit brain inflammation. Further studies should investi-
gate the effect of mercury and thimerosal alone or
together with allergic and non-immune triggers.
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